Dermatological care is experiencing a profound paradigm shift away from frequent injections toward scalable, easy-to-take oral medications. Highlighting these oral psoriasis treatment advances, Johnson & Johnson presented robust two-year data from its Phase 3 ICONIC-LEAD study. Their pioneering drug, ICOTYDE (icotrokinra), stands as the first and only targeted oral peptide engineered to precisely block the IL-23 receptor. Over 70% of tracking patients achieved near-total skin clearance, proving that pill-based alternatives can deliver long-lasting, durable therapeutic results without requiring intensive blood monitoring.
About the Author
